47754 Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 

polyunsaturated fatty acid accumulates 

in the brain during development, and 

has been implicated in learning and 

memory development. DEA, a 

metabolite derived from DHA, also has 

been shown to accelerate neuronal 

growth and development. In vitro 

studies in which neural progenitor cells 

were treated with DEA derivatives 

showed an increase in the number of 

somatic neurons produced after 

differentiation. 

Potential Commercial Applications 

• Neurogenesis, 

• Neurite growth, 

• Synaptogenesis, 

• Therapeutics for traumatic brain 

injury, spinal cord injury, peripheral 

nerve injury, stroke, multiple sclerosis, 

autism, Alzheimer’s disease, 

Huntington’s disease, Parkinson’s 

disease, and amyotrophic lateral 

sclerosis. 

Inventors: Erika Englund (NCATS), 

Juan Marugan (NCATS), Samarjit 

Patnaik (NCATS), Hee-Yong Kim 

(NIAAA). 

Intellectual Property: HHS Reference 

No. E–070–2012/0, U.S. Provisional 

Patent Application 61/624,741 filed 

April 16, 2012 (expired), International 

Patent Application PCT/US2013/032333 

filed March 15, 2013 (expired), U.S. 

Patent 9,422,308; German Patent 

602013016154.2, French Patent 

2847178, and UK Patent 2847178. 

Licensing Contact: Michael 

Shmilovich, Esq, CLP; 301–435–5019; 

shmilovm@nih.gov. 

Dated: October 5, 2017. 

Michael Shmilovich, 

Senior Licensing and Patenting Manager, 

National Heart, Lung, and Blood Institute, 

Office of Technology Transfer and 

Development . 

[FR Doc. 2017–22146 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Immune 

System Plasticity in Dental, Oral, and 

Craniofacial Diseases. 

Date: November 1, 2017. 

Time: 2:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Yi-Hsin Liu, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4214, 

MSC 7814, Bethesda, MD 20892, 301–435– 

1781, liuyh@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–17– 

263: Innovation for HIV Vaccine Discovery. 

Date: November 3, 2017. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Barna Dey, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3184, 

Bethesda, MD 20892, 301–451–2796, bdey@

mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Epidemiology, Ethical and 

Population Sciences. 

Date: November 3, 2017. 

Time: 2:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Gniesha Yvonne 

Dinwiddie, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 3137, Bethesda, MD 20892, 

dinwiddiegy@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Systems Science and Health in the 

Behavioral and Social Science. 

Date: November 7, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Ping Wu, Ph.D., Scientific 

Review Officer, HDM IRG, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3166, 

Bethesda, MD 20892, 301–451–8428, wup4@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Improving Smoking Cessation in 

Socioeconomically Disadvantaged 

Populations via Scalable Interventions. 

Date: November 7, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Kristen Prentice, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3112, 

MSC 7808, Bethesda, MD 20892, 301–496– 

0726, prenticekj@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Digestive Sciences. 

Date: November 8–9, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Martha Garcia, Ph.D., 

Scientific Reviewer Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2186, 

MSC 7818, Bethesda, MD 20892, 301–435– 

1243, garciamc@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Computational, Modeling, and 

Biodata Management. 

Date: November 8, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road NW., 

Washington, DC 20015. 

Contact Person: Allen Richon, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 

MSC 7892, Bethesda, MD 20892, 301–379– 

9351, allen.richon@nih.hhs.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Pathophysiology of 

Neurodevelopmental Disorders. 

Date: November 8, 2017. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Boris P Sokolov, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217A, 

MSC 7846, Bethesda, MD 20892, 301–408– 

9115, bsokolov@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–17– 

171: Cancer Tissue Engineering Collaborative 

Research. 

Date: November 8, 2017. 

Time: 12:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 47755 

Contact Person: Angela Y Ng, Ph.D., MBA, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6200, 

MSC 7804, Bethesda, MD 20892, 301–435– 

1715, nga@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Pregnancy, 

Placentation, and Neonatology. 

Date: November 9, 2017. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Gary Hunnicutt, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6164, 

MSC 7892, Bethesda, MD 20892, 301–435– 

0229, gary.hunnicutt@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 6, 2017. 

Anna Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22139 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

patent applications listed below may be 

obtained by emailing the indicated 

licensing contact at the National Heart, 

Lung, and Blood, Office of Technology 

Transfer and Development Office of 

Technology Transfer, 31 Center Drive 

Room 4A29, MSC2479, Bethesda, MD 

20892–2479; telephone: 301–402–5579. 

A signed Confidential Disclosure 

Agreement may be required to receive 

copies of the patent applications. 

SUPPLEMENTARY INFORMATION: This 

notice is in accordance with 35 U.S.C. 

209 and 37 CFR part 404 to achieve 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. A description of the 

technology follows. 

Small Interfering RNA Inhibition of 

Cannabanoid-1 Receptor (CB1R) for 

Treating Type 2 Diabetes 

Description of Technology: The 

invention pertains to the use of glucan 

encapsulated non-immunostimulatory 

small interfering RNAs (siRNAs) to treat 

type-2 diabetes. Endocannabinoids (EC) 

are lipid signaling molecules that act on 

the same cannabinoid receptors that 

recognize and mediate the effects of 

endo- and phytocannabanoids. EC 

receptor CB1R activation is implicated 

in the development of obesity and its 

metabolic consequences, including 

insulin resistance and type 2 diabetes. 

Beta-cell loss has been demonstrated in 

a Zucker diabetic fatty (ZDF) rat model 

of type-2 diabetes through CB1Rmediated activation of a macrophagemediated inflammatory response. 

Conversely, rats treated with a 

peripheral CB1R antagonist restores 

normoglycemia and preserves beta-cell 

function. Similar results are seen 

following selective in vivo knockdown 

of macrophage CB1R by daily treatment 

of ZDF rats with the instant D-glucanencapsulated CB1R Small interfering 

RNA (siRNA). Knock-down of CB1R 

with using glucan encapsulated siRNA 

may represent a new commecializable 

method of treating type-2 diabetes or 

preventing the progression of insulin 

resistance to overt diabetes. 

Potential Commercial Applications: 

Treatment of obesity, insulin resistance, 

and diabetes. 

Development Stage: In vivo data 

available. 

Inventors: George Kunos, Tony 

Jourdan (NIAAA), Michael Czech, 

Myriam Aouadi. 

Intellectual Property: HHS Reference 

No. E–103–2013/0, U.S. Provisional 

Patent Application 61/839,239 filed 

June 25, 2013, International Patent 

Application PCT/US2014/043924 filed 

June 24, 2014, European Patent 

Application 14818342.9 filed June 24, 

2014 and U.S. Patent Application 14/ 

900,951 filed June 24, 2014. 

Licensing Contact: Michael 

Shmilovich, Esq, CLP; 301–435–5019; 

shmilovm@nih.gov. 

Dated: October 5, 2017. 

Michael Shmilovich, 

Senior Licensing and Patenting Manager, 

National Heart, Lung, and Blood Institute, 

Office of Technology Transfer and 

Development. 

[FR Doc. 2017–22147 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Neurological Sciences 

Training Initial Review Group; NST–2 

Subcommittee. 

Date: October 23, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Crystal City, 2399 Jefferson 

Davis Highway, Arlington, VA 22202. 

Contact Person: Elizabeth Webber, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–1917, Webbere@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; R13 Review. 

Date: October 26, 2017. 

Time: 9:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Ernie Lyons, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–4056, lyonse@ninds.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; F32 and K22 Review. 

Date: November 2–3, 2017. 

Time: 8:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES